secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2022-07-08T23:59:59+00:00
Accession:  0001193125-22-190531
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aileron Therapeutics CMO Vojislav Vukovic departs; severance agreement reached
------------------------------------------------------------------------------

- Chief Medical Officer Vojislav Vukovic, M.D., Ph.D. separated from Aileron on July 8, 2022.
- Separation was not due to any disagreement with the company regarding operations, policies, or practices.
- Severance includes nine months of semi-monthly salary continuation and COBRA premium payments.
- Separation agreement contains customary release of claims, non-solicit, non-disparagement, and cooperation covenants.
- No successor or interim CMO has been announced as of the filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522190531/0001193125-22-190531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522190531/d367608d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-190531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer